Onesource Specialty Pharma Limited: General Update'.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
OneSource Specialty Pharma reported FY25 consolidated CDMO (Contract Development and Manufacturing) segment revenue of Rs. 14,448.53 million, a sharp jump from Rs. 1,754.54 million in FY24, largely reflecting the Stelis Biopharma merger integration. The CDMO segment narrowed its pre-tax loss to Rs. 670.66 million in FY25 from Rs. 3,911.65 million in FY24, showing clear improvement. On a standalone basis, the company swung to a profit after tax of Rs. 200 million in FY25 from a loss of Rs. 3,649.34 million in FY24, with Q4 FY25 delivering a strong standalone profit after tax of Rs. 1,748.77 million. Statutory auditors Deloitte Haskins & Sells issued an unmodified (clean) opinion on the audited results. Separately, the board approved in-principle consolidation of its Singapore subsidiaries (Stelis Pte Ltd and Strides Softgel Pte Ltd) into OneSource Specialty Pte Ltd; since all entities are wholly owned, there is no impact on consolidated financials. The company also fully repaid its listed non-convertible debentures during FY25, releasing related charges on assets.
Strong revenue growth and a return to profitability signal improving operational performance post-merger, while full debenture repayment reduces debt obligations. The Singapore consolidation simplifies the group structure with no dilution or material financial impact for shareholders.